Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 14, 2021

Primary Completion Date

December 13, 2025

Study Completion Date

December 13, 2025

Conditions

Lupus Erythematosus, Systemic

Interventions

BIOLOGICAL

single dose of CNCT19

Autologous 2nd generation CD19-directed CAR-T cells, infusion intravenously.

Trial Locations (1)

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou